Drug intelligence / Profile preview

TBC-F357 + TBC-F349

Development stage: Unknown
Lead developer: Therion Biologics
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

TBC-F357 + TBC-F349 is a combination of two recombinant fowlpox virus (FPV) vaccines designed for HIV treatment. TBC-F357 encodes HIV env/gag proteins, while TBC-F349 encodes HIV tat/rev/nef-RT proteins. They are administered intramuscularly at a dose of 5 x 10^8 each construct as part of a prime-boost vaccination strategy, following initial priming with MVA (Modified Vaccinia Ankara) vaccines.

Other names: rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT

Beyond the preview

Go deeper on TBC-F357 + TBC-F349.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBC-F357 + TBC-F349.

Explore the full profile